Toxoplasmosis Research Institute

Monthly screening with a novel point of care test that meets WHO criteria for a perfect test presents a new method to block transmission and illness in babies because it enables prompt effective treatment.

The high prevalence of chronic and incidence of recent T. gondii infections in fathers of congenitally infected children indicates that T. gondii infections cluster within families in North America.

The National Collaborative Chicago-based Congenital Toxoplasmosis Study (NCCCTS) is a study that began with figuring out how to best treat children with congenital toxoplasmosis who were suspected to have severe damage.

Let’s start with a statistic: almost 2,000 citations a year. One paper by Paul Meier,…has been cited more often, by a wide margin, than any other paper in the field. At last count it was the fifth most cited research paper of all time, in any field.

... We have made a vaccine against toxoplasmosis using only CD8 epitopes. This vaccine stimulates cellular immune responses to kill Toxoplasma parasites where they hide inside different tissue cells of the host.

Toxoplasma infections are caused by oocysts and encysted bradyzoites endemically and in epidemics in North, Central and South America. We are currently using systems analyses, bioinformatics and big data to understand connectedness of findings and their practical utility for humans. As well as to understand the biology of each life cycle stage and interrupt transmission to humans globally in a cost effective manner.

Potent tetrahydroquinolone can eliminate toxoplasmosis and malaria

Varied Mechanisms of persistence

Educational Programs, Epidemiology, Screening during gestation in Morocco Colombia and Panama